NASDAQ:RUBY - Rubius Therapeutics Stock Price, News, Headlines & Rumors

Rubius Therapeutics trades on the NASDAQ under the ticker symbol "RUBY."

4 Wall Street analysts have issued 12-month price targets for Rubius Therapeutics' stock. Their forecasts range from $37.00 to $40.00. On average, they expect Rubius Therapeutics' share price to reach $38.50 in the next year. This suggests a possible upside of 72.5% from the stock's current price. View Analyst Price Targets for Rubius Therapeutics.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rubius Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Rubius Therapeutics.

Some companies that are related to Rubius Therapeutics include BIO-TECHNE (TECH), Ablynx (ABLYF), China Biologic Products (CBPO), Aerie Pharmaceuticals (AERI), argenx (ARGX), Halozyme Therapeutics (HALO), Crispr Therapeutics (CRSP), Spark Therapeutics (ONCE), Acceleron Pharma (XLRN), Regenxbio (RGNX), Repligen (RGEN), Momenta Pharmaceuticals (MNTA), Atara Biotherapeutics (ATRA), Sangamo Therapeutics (SGMO) and Denali Therapeutics (DNLI).

(RUBY) raised $200 million in an IPO on Wednesday, July 18th 2018. The company issued 9,500,000 shares at a price of $20.00-$22.00 per share. J.P. Morgan, Morgan Stanley, Jefferies and Leerink Partners acted as the underwriters for the IPO.

Rubius Therapeutics' quiet period expires on Monday, August 27th. Rubius Therapeutics had issued 10,483,000 shares in its IPO on July 18th. The total size of the offering was $241,109,000 based on an initial share price of $23.00. During the company's quiet period, insiders and underwriters involved in the IPO are prevented from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

Press coverage about RUBY stock has been trending somewhat positive on Tuesday, Accern reports. The research firm identifies negative and positive press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Rubius Therapeutics earned a news impact score of 0.22 on Accern's scale. They also gave media stories about the company an impact score of 45.90 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days. View Recent Headlines for Rubius Therapeutics.

Shares of RUBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of RUBY stock can currently be purchased for approximately $22.32.

Rubius Therapeutics has a market capitalization of $1.84 billion. Rubius Therapeutics employs 83 workers across the globe.

Rubius Therapeutics' mailing address is 325 VASSAR STREET SUITE 1A, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-679-9600 or via email at [email protected]